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Abstract
Background: The mortality of cervical cancer in Longnan is as high as 39/10 million, ranking first in China.
Methods: Between 2012 to 2016, 329 samples with cervicitis, cervical intraepithelial neoplasia grade 1 to 3
(CINI to III), and invasive squamous cell carcinoma (SCC) were collected. HPV genotypes were examined with
a validated kit for 23 different HPV subtypes.
Results: Compared to cervicitis, the HPV positivity is significantly higher in CINI, CIN II/III, and SCC (38.60%,
74.60%, 87.50% and 89.05%, P < 0.001) and the positivity is also higher in SCC compared to CINI (P < 0.01).
The most frequently detected genotypes were HPV16 in cervicitis, HPV16, 58 and 52 in CINI and CIN II/III, and
HPV16, 58 and 18 in SCC groups. HPV16 positivity in cervicitis, CINI, CIN II/III, and SCC patients were 45.46%,
46.81%, 60.32% and 78.69%, respectively. Compared to cervicitis and CINI, the odds ratios (OR) for SCC in
HPV16 positive patients were 2.96 (95% confidence interval [CI]: 1.09–8.00, P < 0.05) and 4.20 (95% confidence
interval [CI]: 2.05–8.61, P < 0.001), respectively. In addition, the multiple infections in cervicitis, CINI, CINII/III and
SCC group are 9.09%, 27.66%, 26.98% and 25.41% and HPV16 + 58 was the most common combinations.
Conclusion: These findings highlight the key role of HPV16, 58, 52 and 18 in the development of CIN and
SCC in Longnan women and a fully aware of regional differences in HPV genotype distribution are tasks for
cervical cancer control and prevention.
Keywords: Human papillomaviruses, Cervicitis, Cervical intraepithelial neoplasia grade I to III, Invasive
squamous cell carcinoma
Background
Human papillomaviruses (HPV), double-stranded and
non-enveloped DNA viruses (7 ~ 8 kb long), are a group
of remarkably diverse DNA viruses from the Papilloma-
viridae family, which are causally involved in the etiology
of various benign and malignant neoplastic lesions of
mucosal and skin epithelium [1, 2]. Currently, more than
200 different HPV genotypes have been identified.
Genotypes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58
and 59 are regarded as high risk types (hr-HPV) because
they are identified in high-grade squamous intraepithe-
lial lesions (HSIL) and invasive cervical cancer tissues
[3–5]. On the other hand, the genotypes HPV6 and 11
are considered as low-risk types [4, 6].
Cervical cancer (CC) is a major fatal malignancy
among women, causing about 265,700 deaths annually
world-wide. Nearly 90% of cervical cancer deaths occur
in developing countries, such as China [7]. The cervical
cancer incidence in China is high, with 132,300 new
cases each year, yielding a rate of 27 per 100,000 women
[8]. Epidemiological studies and experimental data verify
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that persistent HPV infection is considered to play a key
role in the development of CC [9]. Cervical intraepithelial
neoplasia (CIN) reflects a continuous and progressive CC
process, and high grade squamous intraepithelial lesions
(HSIL) with HPV infection, can develop and progress to
CC over a period of 8 to 12 years [10].
The prevalence of HPV infection and the reported
type-specific distribution varies greatly by geographic
region and ethnicity. For example, HPV16 is slightly
more prevalent in Europe and North America, HPV 31
is more prevalent in South/Central America, HPV 33
and 45 are more prevalent in Africa, and HPV 52 and
58 are more prevalent in Asia [9, 11–17]. Furthermore,
the data from mainland China indicated that HPV16,
18, 33, and 58 were the most common types in women
with CC in Henan, central China [18], whereas HPV16,
58, 18 and 33 were the most prevalent types in CIN2+
(high-grade cervical lesions, including CINII/III, and
CC) in women in Liaoning, northeast China [19], and
HPV16 and 58 were the most common types in CC and
high-grade precancerous lesions in Chengdu, south-
western China [20].
Longnan of Gansu Province, located in the remote
areas of Northwest of China, is the high incidence areas
of cervical cancer and cervical cancer mortality as high
as 39/10 million, ranking first in China [21]. This study
aims to investigate the prevalence and distribution of
HPV oncogenic genotypes in patients with cervicitis,
CINI, CINII/III, or invasive squamous cell carcinoma
(SCC) in Longnan. The results will help to establish
more cost-effective follow up and guiding significance
for cervical cancer prevention.
Methods
Study subjects
A total of 329 Longnan patients aged 17 ~ 79 years sam-
ples were initially included in the present study between
January 1, 2012, and January 30, 2016: 57 in the cervi-
citis group, 63 in the CINI group, 72 in the CINII/III
group, and 137 in the SCC group. All the samples were
obtained from patients who underwent biopsies with
colposcopy or advanced operations. In all of samples,
305 were obtained at the No.1 Hospital of Longnan City
as well as 24 samples from Gansu Provincial Cancer
Hospital. All patients gave written informed consent for
their participation. This study has been approved by the
Ethics Committees of Northwest University for National-
ities prior to its start. All the samples were formalin-fixed
and paraffin-embedded. All specimens were evaluated by
at least 2 experienced pathologists in their respective
hospital’s pathology department. Cervicitis, CINI, CINII/
III and squamous cervical cancer (SCC) were diagnosed
according to the standard criteria [22].
HPV genotype screening using the human papillomavirus
genotyping kit
The Human Papillomavirus Genotyping kit for 23 Types
was produced by Yaneng Bioscience co., LTD (Shen
Zhen, China), and the kit was applied for with permit
number 3400994 in 2008 by the Fresh Armed State Drug
Administration, China. The kit was used to perform
Polymerase chain reaction (PCR) to amplify the L1 gene
in conjunction with reverse dot blot (RDB) analysis to
identify the HPV subtypes. This method offers a simple
testing strategy involving a membrane chip that can
detect infections from multiple HPV subtypes, including
18 high-risk types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 68, 73, 83 and MM4) and 5 low-risk
types (HPV 6, 11, 42, 43 and 44). This method had a
sensitivity of 103 copies/ml and a specificity of 99%; β-
globin was used as an internal positive control [23].
DNA extraction and polymerase chain reaction (PCR)
conditions
DNA was extracted from 4–5 serial sections (4 μm
thick) by hot dehiscing using the Human Papillomavirus
Genotyping kit for 23 Types, according to the manufac-
turer’s instructions. The tissues prepared for extraction
included representative tumor tissues and the adjacent
normal tissue. The quality of the extracted DNA was
verified using a spectrophotometer (260/280 nm ultra-
violet light). The extracted DNA was concentrated by
high-speed centrifugation at 4 °C. For each PCR reac-
tion, 5 μL extracted concentrated DNA was used in a
final reaction volume of 25 μL. The PCR amplification
conditions were as follows: preheating at 95 °C for
10 min, followed by 40 cycles of denaturation at 94 °C
for 30 s, annealing at 42 °C for 90 s, and extension at
72 °C for 30 s, with a final extension at 72 °C for 5 min.
The amplification were then denatured and subjected to
hybridization.
To test the quality of the DNA, the kit was also used
to amplify the housekeeping gene β-globin within the
same reactions as an internal positive control. We also
used a verified HPV multiple infection cervical intrae-
pithelial neoplasia sample as a positive control and
distilled water as a negative control; all control samples
were subject to the same treatments and processed at
the same time as the experimental samples. To ensure
the samples were not contaminated within the lab, every
test was carried out with fresh wash buffer and all
samples were independently tested in two isolated labs
by blind assignment.
HPV detection and typing
We use the reverse dot blot (RDB) method for HPV
detection and typing. The 25 μL reaction volumes
containing the amplified fragments were hybridized to
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the dot blot membrane in 6 mL hybridization solu-
tion (2 × SSC, 0.1%SDS) at 51 °C for 2 h. After a
stringent wash, the hybridized membrane was probed
by adding a streptavidin-horseradish peroxidase con-
jugate (which binds to the biotinylated PCR products)
and a substrate (3,3’,5,5’-Tetramethylbenzidine) to gen-
erate a blue precipitate at the site of the probe dot.
The results were inspected by macroscopic observa-
tion, and the results were deemed reliable when the
PC (positive control) dot appeared as a clear round
blue dot. A clear round blue dot was scored as posi-
tive for the corresponding HPV subtype, a dilute blue
dot was scored as weakly positive, and the absence of
a dot was scored as negative.
Statistical analysis
Statistical analysis was performed using SPSS version
19.0 (SPSS, Chicago, IL). Differences between groups
were examined using the χ2, or Fisher’s exact probability
test according to the characteristics of the data distribu-
tion. The odds ratio (OR) and relative 95% confidence
interval (CI) were calculated. The significance level α
was set at 0.05.
Results
Genotypes detected in Cervicitis, CINI, CINII∕III and SCC
We identified 329 eligible patients with a mean age of
43.5 years (range, 17 ~ 79) from the medical records.
Of these patients, 57 were confirmed as cervicitis, 63
were CINI, 72 were CINII∕III, and 137 cases were SCC.
The HPV positive rates in the cervicitis, CINI,
CINII∕III and SCC were 38.60% (22/57), 74.60% (47/
63), 87.50% (63/72) and 89.05% (122/137), respect-
ively; the HPV positive rate was significantly higher in
CINI, CINII∕III and SCC than that in cervicitis (P <
0.001). and the positivity is also higher in SCC com-
pared to CINI (P < 0.01. Fig. 1).
The distribution of HPV genotypes according to
cervical lesions is shown in Fig 2. HPV16 was the most
common genotype in cervicitis, accounting for 45.46%
(10/22). In the CINI group, HPV16 was the most
common genotype, accounting for 46.81% (22/47),
followed by HPV58 (21.28%, 10/47), HPV52 (17.02%,
8/47), HPV33 (12.77%, 6/47), HPV 51 (6.38%, 3/47) and
59 (6.38%, 3/47). For the CIN II∕III group, HPV16 was
also the most common genotype, accounting for 60.32%
(38/63), followed by HPV58 (25.40%, 16/63), HPV52
(12.70%, 8/63), HPV31 (6.35%, 4/63) and 33 (6.35%, 4/63).
The 5 most common genotypes in patients with SCC were
HPV16 (78.69%, 96/122), HPV58 (20.49%, 25/122),
HPV18 (6.56%, 8/122), HPV59 (4.92%, 6/122) and 52
(4.10%, 5/122), in descending order. None genotype of the
differences between groups were significant except
HPV16 infection in SCC compared to cervicitis, CINI and
CINII∕III (P < 0.001, P < 0.01. Fig. 2).
OR for HPV16 infection
Because HPV16 was significantly higher in invasive SCC,
logistic regression analysis was used to calculate the
odds ratios (OR) and 95% confident intervals (95%CI) of
such infections. Compared to cervicitis and CINI, the
odds ratios (OR) for SCC in HPV16 positive patients
were 2.96 (95% confidence interval [CI]: 1.09–8.00,
P < 0.05) and 4.20 (95% confidence interval [CI]:
2.05–8.61, P < 0.001, respectively (Table 1).
HPV genotypes of multiple infections in Cervicitis, CINI,
CINII∕III and SCC
Some women were infected with 2 or 3 types of HPV
simultaneously (Table 2). Compared to cervicitis (9.09%,
2/22), more patients with CINI, CIN II∕III and SCC had
multiple HPV infections, however, as the cervical lesion
grade increased, the prevalence of multiple HPV infec-
tions gradually deceased (27.66%, 13/47; 26.98%, 17/63
and 25.41%, 31/122, respectively). Double infections
accounted for the majority of multiple infections, 4.55%(1/
22), 21.28%(10/47), 20.64%(13/63) and 21.31%(26/122)
for cervicitis, CINI, CIN II∕III and SCC respectively. Of
those, HPV16 + 58 was the most common combina-
tions, and HPV52 + 33 in CINI subgroup, HPV16 + 33
and HPV16 + 52 in CIN II∕III subgroup were also com-
mon genotypes combination. In the cervicitis, CINI,
CIN II∕III and SCC subgroups, 4.5%(1/22), 6.38%(3/47),
6.35%(4/63), 4.10% (5/122) of patients had triple HPV
infections. The combinations and prevalence of the
HPV genotypes in multiple infections for each cervical
lesion group and subgroup are specified in Table 3.
Fig. 1 Prevalence of HPV infection in the study groups. *** P < 0.001
CINI, CINII/III, SCC vs. cervicitis; ## P < 0.01 SCC vs. CINI. Percentages for
co-infections with two or more HPV strains were calculated separately
for each one. Abbreviations: HPV, human papillomavirus; CIN, cervical
intraepithelial neoplasia; SCC, squamous cell carcinoma
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Discussion
Our data showed that 38.60% of patients with cervicitis,
74.60% with CINI, 87.50% with CINII∕III, and 89.05%
with SCC were positive for HPV DNA. HPV infection
rates were significantly higher in CINI, CINII∕III, and
invasive SCC than in cervicitis patients, but they never
reached 100%. In addition, in our population, HPV 16
was the dominant genotype and HPV 33, 53, 58 and 59
were the second dominant genotypes for cervicitis. HPV
genotypes 16, 58, and 52 were the dominant high-risk
HPV in patients with CINI and CINII∕III, however for
invasive SCC, the dominant high-risk HPV were 16, 58
and 18. Besides of the genotypes suggested above, HPV
6, 11, 31, 33, 51, 56 and 59 also were detected. In some
reports in which HPV16, 18, and 45, HPV16, 18 and 33
or 16, 18 and 58 were most commonly detected in cervi-
citis [11, 24–26], CINI, CINII∕III and SCC patients. Des-
pite the small sample size of our subgroup, the
dominant genotypes remained stable across the cervi-
citis, CINI, CINII∕III and SCC groups, which supported
the credibility of our data. In addition, HPV16 was sig-
nificantly associated with SCC, the ORs were 2.96 (CI:
1.09–8.00) and 4.20 (CI: 2.05–8.61, respectively, when
compared to cervicitis and CINI. The absence of a simi-
lar significant association between other genotypes may
have been due to the small size of study groups.
In our group of CINI, CINII∕III and SCC patients, the
positivity for HPV DNA are consistent with those in
most other studies [11, 24–30]. For example, the reports
from Shanghai of 239 patients with CINI and USA of
411 patients with CINII∕III, in which the rates of HPV
DNA positivity were 74.9% and 82.0–92.0%. For the
regions of worldwide, the rate of HPV DNA positivity in
SCC was 87.0–90.9%. In addition, the positivity of
HPV16 infection in CINI, CINII∕III and SCC patients is
46.81%, 60.32% and 78.69% respectively, which is also
consistent with the most reports [11, 24, 31, 32]. These
evidences further suggested that the performance of
HPV detection kit is credible and our data likely reflect
the real association pattern between HPV infection and
cervical cancer or precancerous lesions in local area.
The distribution of dominant HPV genotypes showed
obvious regional differences [33]. HPV18 is reported to
be one of the two most carcinogenic HPV genotypes
(HPV16 and 18), accounting for 10 ~ 15% of cervical
cancers [11, 24, 32]. In our population, the prevalence of
HPV18 in patients with cervicitis, CIN I, CIN II/III and
invasive SCC were 0%, 2.13%, 1.59% and 6.56%, respect-
ively. The overall prevalence rate of HPV18 is very lower,
but consistent with a recent Korea report, where only 6
(2.5%) out of the 243 high-risk HPV positive subjects
showed HPV18 infection [34]. HPV52 is also considered
as a high-risk genotype and is especially frequent in
Northern America, Africa, and Asia [35, 36]. In our
population, the prevalence of HPV52 in patients with
cervicitis, CIN I, CIN II/III and invasive SCC were
4.55%, 17.02%, 12.70% and 4.10%, respectively and was
largely higher than in other reports, in which HPV52
prevalent rates ranged up to 2.4% in women with normal
cytological findings, 5.1% in women with CIN II/III and
were 2.5% in women with SCC [36]. In present study,
HPV 58 is a dominant high-risk genotype and the preva-
lence of HPV58 in patients with cervicitis, CIN I, CIN
II/III and invasive SCC was 9.09%, 21.28%, 25.40 and
20.49%, respectively. Although the overall prevalence
Fig. 2 Distribution of HPV infection in the study groups. ** P< 0.01 vs. SCC; *** P< 0.001 vs. SCC. Percentages for co-infections with two or more HPV
strains were calculated separately for each one. Abbreviations: HPV, human papillomavirus; CIN, cervical intraepithelial neoplasia; SCC, squamous cell
carcinoma
Table 1 ORs of HPV16 for SCC
OR 95% CI P
2.96 (Compared to cervicitis) 1.09 – 8.00 < 0.05
4.20 (Compared to CIN I) 2.05 – 8.61 < 0.001
Abbreviations: HPV human papillomavirus, CIN cervical intraepithelial neoplasia,
SCC squamous cell carcinoma, OR odds ratio, CI confidence interval
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rate of HPV58 in our research is very higher than the
reports of Japanese and world, in which HPV58 preva-
lence rates are 7.0% in patients with CIN II/III and 3.3%
~ 13.3% in patients with SCC [10, 37], our result is
consistent with some recent Chinese reports [33, 38],
where 16.4%, 20.1%, 23.5% and 31.4% patients with
cervicitis, CIN I, CIN II/III and invasive SCC and 29.1%
and 24.3% patients with CIN II/III and invasive SCC
showed HPV58 infection.
Our data suggested that more patients with CINI, CIN
II∕III and SCC had multiple HPV infections compared to
cervicitis, however, the rates of multiple HPV infections
in CIN I, CIN II/III and SCC patients showed a slightly
decreasing trend with severity of lesions. Although this





cervicitis 90.91% (20/22) 4.55% (1/22) 4.5% (1/22) 9.09% (2/22)
CIN I 72.34% (34/47) 21.28% (10/47) 6.38% (3/47) 27.66% (13/47)
CIN II/III 73.02% (46/63) 20.64% (13/63) 6.35% (4/63) 26.98% (17/63)
SCC 74.59% (91/122) 21.31% (26/122) 4.10% (5/122) 25.41% (31/122)
Abbreviations: HPV human papillomavirus, CIN cervical intraepithelial neoplasia, SCC squamous cell carcinoma
Table 3 Combinations of HPV types in multiple infection in the study groups
Genotype Cervicitis CIN I CIN II/III SCC
Conbinations of HPV types in double infections
HPV16+18 1.64% (2/122)
HPV16+33 4.76% (3/63) 1.64% (2/122)
HPV16+52 4.76% (3/63)
HPV16+58 4.26% (2/47) 6.35% (4/63) 9.84% (12/122)








HPV58+other types 1.59% (1/63) 0.82% (1/122)













Abbreviations: HPV human papillomavirus, CIN cervical intraepithelial neoplasia, SCC squamous cell carcinoma
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finding is partially consistent with the results of previous
studies, in which Francois et al. and Meizhu Xiao et al.
found that the rates of multiple hr-HPV infections in CINII,
CINIII, and CC patients declined gradually [38, 39], the
rates of multiple HPV infections of our survey was signifi-
cantly lower than in these reports. This difference may
occur because the prevalence of HPV-positive status also
vary varies among geographic locations and populations.
Moreover, the small size of group in our study may be one
of the reason of lower positivity of multiple HPV infections.
However, in a worldwide pooled analysis of 167 adenocar-
cinoma of the cervix patients, the multiple-infection rate
was 8.9%, obviously lower than the simple infection preva-
lence of 91.1% [18]. Thus, our data which reflected Multiple
HPV infections might be indeed be associated with the
development of cervical lesions, or women with multiple
HPV infections might be more susceptible to cervical
carcinogenesis, or multiple HPV infections might produce
conditions that confer immunological protection against
persistent infection [40].
Our data indicated that the combination of HPV16 + 58
plays a dominant role in all cervical lesion groups, con-
trary to findings in the Jewish Israeli population and in
Austrians, but in agreement with findings in women in
Beijing, China [41–43]. Thus, the results of this study
strongly support the key role of HPV16 and 58 in the de-
velopment of CC and CIN in women in LongNan, China.
Conclusions
Overall, as demonstrated in our study population, geno-
types 16, 58, 52 and 18 are among the predominant
HPV and HPV infection increased with cervical lesion,
regional differences in HPV genotype distribution and
the real carcinogenic HPV revealing need to be mindful
in the HPV control and prevention.
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